<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159015</url>
  </required_header>
  <id_info>
    <org_study_id>586</org_study_id>
    <nct_id>NCT01159015</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers</brief_title>
  <official_title>A Multi-center, Double-masked, Randomized, Placebo-controlled, Parallel-group Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy, Normal Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the safety of KetoNaph ophthalmic solution in&#xD;
      healthy adult subjects and in pediatric subjects with a history or family history of ocular&#xD;
      allergy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With at Least One Adverse Event.</measure>
    <time_frame>42 days</time_frame>
    <description>An adverse event was defined as unfavorable and unintended sign, symptom, or disease temporally associated with the use of a test article, whether or not considered related to test article.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">534</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>KetoNaph</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KetoNaph Ophthalmic Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of KetoNaph Ophthalmic Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KetoNaph</intervention_name>
    <description>Ophthalmic Solution administered BID for 6 weeks</description>
    <arm_group_label>KetoNaph</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle of KetoNaph ophthalmic solution administered bid for six weeks</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects less than 18 years of age, have either a history or family history of ocular&#xD;
             allergy.&#xD;
&#xD;
          -  ocular health within normal limits, including a calculated best-corrected visual&#xD;
             acuity of 0.3 logMar or better, in each eye. For subjects under 10 years old who are&#xD;
             developmentally unable to use the ETDRS chart, visual acuity will be made using the&#xD;
             LEA symbols. For these subjects, 20-foot Snellen equivalent units of 20/63 or better&#xD;
             in both eyes will be required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications or sensitivities to the use of any of the investigational product(s)&#xD;
             or their components.&#xD;
&#xD;
          -  Subjects less than 18 years of age that have had symptoms and/or signs of allergic&#xD;
             conjunctivitis/rhinitis and/or treatment with topical or systemic anti-allergy&#xD;
             therapy, or have had a history of ragweed hypersensitivity during the 21-day period&#xD;
             prior to visit 1.&#xD;
&#xD;
          -  Surgical intervention within three months prior to Visit 1 or during the refractive&#xD;
             surgery within the past 6 months.&#xD;
&#xD;
          -  A known history of retinal detachment, diabetic retinopathy, or active retinal&#xD;
             disease;&#xD;
&#xD;
          -  An active ocular infection (bacterial, viral or fungal&#xD;
&#xD;
          -  Use of any topical ophthalmic agents other than investigational products during study&#xD;
             participation or within 5 days of beginning study treatment.&#xD;
&#xD;
          -  Current or anticipated use of contact lenses during study participation or within 5&#xD;
             days of beginning study treatment.&#xD;
&#xD;
          -  Current, prior (within 14 days of beginning study treatment) or anticipated use of&#xD;
             systemic corticosteroids, and/or any other systemic medications which the Investigator&#xD;
             feels may confound study data or interfere with the subject's study participation.&#xD;
             Prior (within 21 days of beginning study treatment), current or anticipated use of any&#xD;
             topical (including nasal) or systemic anti-allergy medications.&#xD;
&#xD;
          -  Intraocular pressure (IOP) that is less than 5 mmHg or greater than 22 mmHg or have a&#xD;
             normal IOP with a diagnosis of glaucoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuyen Ong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 6, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <results_first_submitted>August 24, 2020</results_first_submitted>
  <results_first_submitted_qc>August 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2020</results_first_posted>
  <disposition_first_submitted>September 27, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>October 6, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 10, 2011</disposition_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>KetoNaph</title>
          <description>KetoNaph Ophthalmic Solution ketotifen fumarate 0.025%, naphazoline HCl 0.05%&#xD;
KetoNaph: Ophthalmic Solution administered BID for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle of KetoNaph Ophthalmic Solution&#xD;
Vehicle: Vehicle of KetoNaph ophthalmic solution administered bid for six weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="357"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="339"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>KetoNaph</title>
          <description>KetoNaph Ophthalmic Solution ketotifen fumarate 0.025%, naphazoline HCl 0.05%&#xD;
KetoNaph: Ophthalmic Solution administered BID for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle of KetoNaph Ophthalmic Solution&#xD;
Vehicle: Vehicle of KetoNaph ophthalmic solution administered bid for six weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="357"/>
            <count group_id="B2" value="177"/>
            <count group_id="B3" value="534"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" spread="17.2"/>
                    <measurement group_id="B2" value="31.0" spread="16.6"/>
                    <measurement group_id="B3" value="31.5" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="304"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least One Adverse Event.</title>
        <description>An adverse event was defined as unfavorable and unintended sign, symptom, or disease temporally associated with the use of a test article, whether or not considered related to test article.</description>
        <time_frame>42 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>KetoNaph</title>
            <description>KetoNaph Ophthalmic Solution ketotifen fumarate 0.025%, naphazoline HCl 0.05%&#xD;
KetoNaph: Ophthalmic Solution administered BID for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of KetoNaph Ophthalmic Solution&#xD;
Vehicle: Vehicle of KetoNaph ophthalmic solution administered bid for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Adverse Event.</title>
          <description>An adverse event was defined as unfavorable and unintended sign, symptom, or disease temporally associated with the use of a test article, whether or not considered related to test article.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>42 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>KetoNaph</title>
          <description>KetoNaph Ophthalmic Solution ketotifen fumarate 0.025%, naphazoline HCl 0.05%&#xD;
KetoNaph: Ophthalmic Solution administered BID for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle of KetoNaph Ophthalmic Solution&#xD;
Vehicle: Vehicle of KetoNaph ophthalmic solution administered bid for six weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Please contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <phone>908-300-9920</phone>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

